NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives
Alnylam Pharmaceuticals (ALNY) books FY 2025 profit as quarterly revenue tops US$1 billion
Alnylam Pharmaceuticals (ALNY) has capped FY 2025 with fourth quarter revenue of US$1,097.0 million and basic EPS of US$1.41, alongside net income of US$186.4 million that continues the company’s recent move into profitability. The company has seen revenue step up from US$593.2 million and basic EPS of US$0.65 loss in Q4 2024 to US$594.2 million with EPS of US$0.44 loss in Q1 2025, US$773.7 million with...